Vera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA Nephropathy

Vera Therapeutics Inc. (NASDAQ:VERA) is one of the best high short interest stocks with huge upside potential. Earlier in June, Vera Therapeutics announced positive topline results from its ongoing global, multicenter, randomized, double-blind, and placebo-controlled ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

The trial met its primary endpoint and showed a statistically significant and clinically meaningful reduction in proteinuria at week 36. The safety profile of atacicept was favorable and comparable to that of the placebo. IgA nephropathy is a kidney disease characterized by the buildup of an immune protein called immunoglobulin A (IgA) in the kidneys. This leads to inflammation and can progressively impair the kidneys’ ability to filter waste from the blood, potentially leading to kidney failure.

Vera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA Nephropathy

A team of scientists in lab coats discussing research near a microscope and petri dishes.

Atacicept is an investigational recombinant fusion protein that inhibits two key cytokines: B-cell activating factor/BAFF and A PRoliferation-Inducing Ligand/APRIL, which are involved in B-cell survival and autoantibody production linked to autoimmune diseases like IgAN. Vera Therapeutics plans to meet with the FDA in the coming weeks to discuss these results and the regulatory pathway for atacicept.

Vera Therapeutics Inc. (NASDAQ:VERA) is a clinical-stage biotechnology company that develops and commercializes transformative treatments for patients with serious immunological diseases.

While we acknowledge the potential of VERA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.